The MTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B- dependent control of c-Myc translation. Curr Biol. 2014; 24:2274-2280.Csibi A. et al. The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation . Curr. Biol. 24 ...
Metabolic pathways that contribute to adiposity and ageing are activated by the mammalian target of rapamycin complex 1 (mTORC1) and p70 ribosomal protein S6 kinase 1 (S6K1) axis1,2,3. However, known mTORC1–S6K1 targets do not account for observed loss-of-function phenotypes, suggesting that...
Les voies de signalisation mTORC1 (mammalian target of rapamycin complex 1) / S6K1 (Ribosomal protein S6 kinase 1) et mTORC2 (mammalian target of rapamycin complex 2) /Akt2 ont été décrites pour jouer un rôle majeur dans l’action de l’insuline. En effet, les souris S6K1-/- ...
cellsandtransgenicmice.ThemTORcomplex(C)1/S6K1blockerrapamycininhibitedthephosphoryla- tionofIRS-1atSer636incellsoverexpressing-Syn,suggestingthatmTORC1/S6K1activationby-Syn causesfeedbackinhibitionofinsulinsignalingviasuppressionofIRS-1function.-Synoverexpression ...
干细胞产业是朝阳产业
Inhibition of the PI3K-Akt-mTORC1-S6K1 axis impairs downregulation of Gfi-1, a negative regulator of Th17 differentiation. Furthermore, the authors show that S6K2, a nuclear counterpart of S6K1, is induced by the PI3K-Akt-mTORC1 axis, binds RORγ, and carries RORγ into the nucleus. ...
在这里,我们证明了mTORC1通过SRPK2促进脂质生物发生,这是rna结合SR蛋白的关键调控因子。 mtorc1激活的S6K1磷酸化SRPK2的Ser494磷酸化,启动CK1磷酸化Ser497。 这些磷酸化事件促进了SRPK2的核易位和SR蛋白的磷酸化。 全基因组转录组分析显示,脂质生物合成酶是mTORC1-SRPK2信号通路的下游靶点之一。
L. (2017) EPRS is a critical mTORC1-S6K1 effector that influences adiposity in mice. Nature 542, 357-361 CrossRef MedlineArif A, Terenzi F, Potdar AA, Jia J, Sacks J, China A, Halawani D, Vasu K, Li X, Brown JM, Chen J, Kozma SC, Thomas G & Fox PL. (2017). EPRS is a...
The present invention is based, in part, on the identification of novel FI.3K-mTORCI-S6K 1 signaling pathway biomarkers predictive of responsiveness to anti-cancer therapies.Roberts, Thomas M.Tong, HaoxuanZhao, JeanBlenis, John
The present invention is based, in part, on the identification of novel FI.3K-mTORCI-S6K 1 signaling pathway biomarkers predictive of responsiveness to anti-cancer therapies.ROBERTS Thomas M.TONG HaoxuanZHAO Jean J.BLENIS John